VIENNA — A single dose of NGM313 demonstrated improvements in multiple noninvasive markers of nonalcoholic steatohepatitis, according to a presentation at the International Liver Congress 2019.
“In [a phase 1] study, we demonstrated a very favorable side-effect profile without any significant adverse events,” Alex M. DePaoli, MD, chief medical officer and vice president of translational research at NGM Biopharmaceuticals, said during his presentation. “What we saw in both of these studies was a very acute and significant reduction in triglycerides and this reduction was

Source link